• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Psoriasiform eruptions secondary to phosphoinositide 3-kinase inhibition.

作者信息

Dewan Anna K, Gupta Sameer, Bach Daniel Q, Jadeja Saagar, Granter Scott, LaCasce Ann, Joyce Robin, Davids Matthew S, Huang Victor, LeBoeuf Nicole R

机构信息

Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee.

Department of Dermatology, The Center for Cutaneous Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.

出版信息

JAAD Case Rep. 2019 Apr 20;5(5):401-405. doi: 10.1016/j.jdcr.2018.03.005. eCollection 2019 May.

DOI:10.1016/j.jdcr.2018.03.005
PMID:31049381
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6479163/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/81d2/6479163/ff4b7b43a40c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/81d2/6479163/abd97dd4b2b0/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/81d2/6479163/ff4b7b43a40c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/81d2/6479163/abd97dd4b2b0/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/81d2/6479163/ff4b7b43a40c/gr2.jpg

相似文献

1
Psoriasiform eruptions secondary to phosphoinositide 3-kinase inhibition.继发于磷酸肌醇3激酶抑制的银屑病样皮疹
JAAD Case Rep. 2019 Apr 20;5(5):401-405. doi: 10.1016/j.jdcr.2018.03.005. eCollection 2019 May.
2
Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.低剂量氟达拉滨和环磷酰胺联合标准剂量利妥昔单抗（LD-FCR）治疗老年初治慢性淋巴细胞白血病患者安全有效：以色列 CLL 研究组经验。
Hematol Oncol. 2019 Apr;37(2):185-192. doi: 10.1002/hon.2580. Epub 2019 Mar 12.
3
Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.氟达拉滨、环磷酰胺及多剂量利妥昔单抗作为慢性淋巴细胞白血病的一线治疗方案
Cancer. 2015 Nov 1;121(21):3869-76. doi: 10.1002/cncr.29605. Epub 2015 Jul 28.
4
Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis.利妥昔单抗、氟达拉滨和环磷酰胺与氟达拉滨和环磷酰胺治疗慢性淋巴细胞白血病的比较：系统评价与荟萃分析。
Crit Rev Oncol Hematol. 2015 Jun;94(3):261-9. doi: 10.1016/j.critrevonc.2015.02.013. Epub 2015 Mar 11.
5
The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies.氟达拉滨、环磷酰胺和利妥昔单抗联合化学免疫疗法在慢性淋巴细胞白血病中的作用：当前证据与争议
Ther Adv Hematol. 2017 Mar;8(3):99-105. doi: 10.1177/2040620716681749. Epub 2016 Dec 1.
6
[Treatment of chronic lymphocytic leukemia with regimen of fludarabine, cyclophosphamide and rituximab].氟达拉滨、环磷酰胺和利妥昔单抗方案治疗慢性淋巴细胞白血病
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Aug;16(4):938-42.
7
Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia.口服低剂量氟达拉滨、环磷酰胺和利妥昔单抗（旧-FCR）联合化疗免疫治疗老年慢性淋巴细胞白血病患者。
Leuk Res. 2014 Aug;38(8):891-5. doi: 10.1016/j.leukres.2014.05.016. Epub 2014 Jun 2.
8
[Chronic lymphocytic leukemia: update on pathophysiology and management].[慢性淋巴细胞白血病：病理生理学与治疗进展]
Rinsho Ketsueki. 2018;59(5):511-520. doi: 10.11406/rinketsu.59.511.
9
Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy.氟达拉滨-环磷酰胺-利妥昔单抗治疗后 B 慢性淋巴细胞白血病的免疫恢复：维持免疫治疗的意义。
Leukemia. 2010 Jul;24(7):1310-6. doi: 10.1038/leu.2010.89. Epub 2010 May 13.
10
Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting.初治环境下慢性淋巴细胞白血病的治疗策略进展
Curr Hematol Malig Rep. 2016 Feb;11(1):61-70. doi: 10.1007/s11899-016-0298-1.

引用本文的文献

1
Incidence of Cutaneous Adverse Events With Phosphoinositide 3-Kinase Inhibitors as Adjuvant Therapy in Patients With Cancer: A Systematic Review and Meta-analysis.癌症患者使用磷酸肌醇3-激酶抑制剂作为辅助治疗时皮肤不良事件的发生率：一项系统评价和荟萃分析。
JAMA Oncol. 2022 Oct 13;8(11):1635-43. doi: 10.1001/jamaoncol.2022.4327.
2
Delayed-onset psoriasiform eruption secondary to a phosphoinositide 3-kinase inhibitor: A case report and literature review.磷酸肌醇3-激酶抑制剂继发的迟发性银屑病样皮疹：一例报告及文献复习
JAAD Case Rep. 2022 Apr 1;24:97-100. doi: 10.1016/j.jdcr.2022.02.043. eCollection 2022 Jun.
3
Psoriasiform Eruption Secondary to PI3K-delta Inhibitor: Expanding the Spectrum of Psoriasiform Paradoxical Reactions?

本文引用的文献

1
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy.癌症中靶向PI3K：对肿瘤细胞、其保护性基质、血管生成和免疫治疗的影响
Cancer Discov. 2016 Oct;6(10):1090-1105. doi: 10.1158/2159-8290.CD-16-0716. Epub 2016 Sep 21.
2
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.一线使用idelalisib治疗慢性淋巴细胞白血病会频繁引发免疫介导的肝毒性。
Blood. 2016 Jul 14;128(2):195-203. doi: 10.1182/blood-2016-03-707133. Epub 2016 May 31.
3
Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity.
PI3K-δ抑制剂继发的银屑病样皮疹：银屑病样矛盾反应的范围正在扩大？
Acta Derm Venereol. 2021 Mar 18;101(3):adv00418. doi: 10.2340/00015555-3783.
因毒性而停止治疗后接受一线idelalisib联合利妥昔单抗治疗的慢性淋巴细胞白血病患者的结局
Cancer. 2016 Aug 15;122(16):2505-11. doi: 10.1002/cncr.30069. Epub 2016 May 16.
4
A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.一项关于idelalisib联合利妥昔单抗用于初治老年慢性淋巴细胞白血病患者的2期研究。
Blood. 2015 Dec 17;126(25):2686-94. doi: 10.1182/blood-2015-03-630947. Epub 2015 Oct 15.
5
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.癌症中的PI3K：异构体的不同作用、激活模式及治疗靶点
Nat Rev Cancer. 2015 Jan;15(1):7-24. doi: 10.1038/nrc3860.
6
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells.伊布替尼对 EGFR 突变型非小细胞肺癌细胞的选择性抗肿瘤活性。
J Natl Cancer Inst. 2014 Sep 10;106(9). doi: 10.1093/jnci/dju204. Print 2014 Sep.
7
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer.PI(3)K p110δ 的失活破坏了调节性 T 细胞介导的对癌症的免疫耐受。
Nature. 2014 Jun 19;510(7505):407-411. doi: 10.1038/nature13444. Epub 2014 Jun 11.
8
Blockade of phosphatidylinositol 3-kinase PI3Kδ or PI3Kγ reduces IL-17 and ameliorates imiquimod-induced psoriasis-like dermatitis.阻断磷酸肌醇 3-激酶 PI3Kδ 或 PI3Kγ 可减少白细胞介素 17 并改善咪喹莫特诱导的银屑病样皮炎。
J Immunol. 2012 Nov 1;189(9):4612-20. doi: 10.4049/jimmunol.1103173. Epub 2012 Sep 28.
9
Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis.T(H)2/T(H)22 细胞因子的逐渐激活和选择性表皮蛋白特征性地表现出急性和慢性特应性皮炎。
J Allergy Clin Immunol. 2012 Dec;130(6):1344-54. doi: 10.1016/j.jaci.2012.07.012. Epub 2012 Aug 27.
10
IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade.白细胞介素-22 诱导的细胞增殖受 PI3K/Akt/mTOR 信号级联调节。
Cytokine. 2012 Oct;60(1):38-42. doi: 10.1016/j.cyto.2012.06.316. Epub 2012 Jul 25.